Evaluation of carbapenem inactivation method-based phenotypic assays for the detection of GES-type carbapenemases in Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii
Authors:
Open Access
- 9 September 2026
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (9)
Abstract
Detection of GES-type carbapenemases remains challenging because of their low prevalence and frequently weak hydrolytic activity against carbapenems. Carbapenem inactivation method (CIM)-based assays are widely used as phenotypic screening tools for carbapenemase detection; however, their performance in large collections of GES producers has not been systematically evaluated. We assessed the performance of CIM, modified CIM (mCIM), and CIM-Tris in a diverse collection of GES-producing clinical isolates, including 110 Enterobacterales and 108 Pseudomonas aeruginosa, recovered from Spanish hospitals (2010–2024), and 10 Acinetobacter baumannii isolates, mostly obtained from a hospital in Egypt. Whole-genome sequencing was carried out for species confirmation and resistome analysis. Meropenem MICs were determined by broth microdilution. Overall, 92.1% of isolates were GES-carbapenemase producers (CP), whereas 7.9% expressed GES-type extended-spectrum β-lactamases (ESBLs). In Enterobacterales (predominantly carrying bla GES-6 ), mCIM improved sensitivity compared with CIM (63.6% vs 40.0%), although many isolates remained undetected due to low meropenem MICs (MIC 50 , 0.5 µg/mL). In CP- P. aeruginosa (mainly bla GES-5 ), CIM, mCIM, and CIM-Tris showed sensitivities of 89.1%, 94.6%, and 100%, respectively; however, CIM-Tris yielded false-positive results in 50% of non-CP isolates (mostly bla GES-1 producers). Meropenem MICs in P. aeruginosa were higher (MIC 50 , >32 µg/mL). In A. baumannii , CIM-Tris improved sensitivity compared with CIM (100% vs 25.0%). These findings indicate that CIM-based methods can detect GES-type carbapenemases, but performance varies according to bacterial species and GES variant, and reduced specificity may occur in isolates producing GES-type ESBLs. Complementary molecular testing may therefore be necessary to ensure accurate detection of GES-type carbapenemases in routine clinical laboratories. IMPORTANCE: GES-type carbapenemases represent an important but underrecognized diagnostic challenge due to their low global prevalence, heterogeneous hydrolytic activity, and the limited performance data available for routine phenotypic detection methods. Although CIM-based assays are widely implemented in clinical microbiology laboratories for carbapenemase screening, their performance against GES-producing organisms has not been comprehensively evaluated across different bacterial genera and GES variants. In this study, we evaluated the performance of CIM, modified CIM (mCIM), and CIM-Tris in a large multicenter collection of well-characterized GES-producing clinical isolates, including Enterobacterales, Pseudomonas aeruginosa , and Acinetobacter baumannii . Our findings demonstrate substantial variability in assay performance according to bacterial species and GES variant. Notably, mCIM improved sensitivity among Enterobacterales with low meropenem MICs, whereas CIM-Tris achieved excellent sensitivity in P. aeruginosa and A. baumannii but at the expense of reduced specificity in isolates producing GES-type ESBLs. To the best of our knowledge, this is the first study directly comparing multiple CIM-based approaches in such a large and taxonomically diverse collection of GES-producing isolates.Keywords
Funding Information
- CIBERES-Centro de Investigación Biomédica en Red. Enfermedades Respiratorias (CB06/06/0058)
- CIBER -Consorcio Centro de Investigación Biomédica en Red (CB21/13/00068)
- CIBER -Consorcio Centro de Investigación Biomédica en Red (CB21/13/00084)
- CIBER -Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095)
- CIBER -Consorcio Centro de Investigación Biomédica en Red (CB21/1300049)
- Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA-2023 Research Project)
This publication has 32 references indexed in Scilit:
- Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050The Lancet, 2024
- Within-host transition to GES-55 during a GES-6-producing Serratia marcescens outbreak: Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenemsInternational Journal of Antimicrobial Agents, 2024
- Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysisThe Lancet Regional Health - Europe, 2023
- Comparison of the performance of three carbapenem inactivation methods for the detection of carbapenemase-producing gram-negative bacilliJournal of Infection and Chemotherapy, 2021
- The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulenceScientific Reports, 2021
- Accuracy and applicability of different phenotypic methods for carbapenemase detection in Enterobacteriaceae: A systematic review and meta-analysisJournal of Global Antimicrobial Resistance, 2020
- Assembly of long, error-prone reads using repeat graphsNature Biotechnology, 2019
- Evaluation of the carbapenem inactivation method (CIM) for detecting carbapenemase activity in enterobacteriaDiagnostic Microbiology and Infectious Disease, 2017
- Mechanistic Basis for the Emergence of Catalytic Competence against Carbapenem Antibiotics by the GES Family of β-LactamasesJournal of Biological Chemistry, 2009